Details about Frank Lichtenberg

Homepage:	http://www8.gsb.columbia.edu/cbs-directory/detail/frl1
Phone:	(212) 854-4408
Postal address:	Courtney C. Brown Professor of Business Columbia University 504 Uris Hall 3022 Broadway New York, NY 10027
Workplace:	National Bureau of Economic Research (NBER), (more information at EDIRC) CESifo, (more information at EDIRC) Finance and Economics Department, Graduate School of Business, Columbia University, (more information at EDIRC)

Access statistics for papers by Frank Lichtenberg.

Last updated 2024-09-28. Update your information in the RePEc Author Service.

Short-id: pli76

---

Jump to Journal Articles Chapters

Working Papers

2022

1. The Effects of Off-label Drug Use on Disability and Medical Expenditure
   NBER Working Papers, National Bureau of Economic Research, Inc
   Also in Ruhr Economic Papers, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen (2022)

2019

2. How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
3. The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis
   CESifo Working Paper Series, CESifo
   See also Journal Article The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis, Forum for Health Economics & Policy, De Gruyter (2018) View citations (2) (2018)

2018

4. The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (5)
   Also in Working Papers, eSocialSciences (2018) View citations (5)
   See also Journal Article THE IMPACT OF NEW DRUG LAUNCHES ON LIFE-YEARS LOST IN 2015 FROM 19 TYPES OF CANCER IN 36 COUNTRIES, Journal of Demographic Economics, Cambridge University Press (2018) View citations (1) (2018)
5. The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
   See also Journal Article The long-run impact of new medical ideas on cancer survival and mortality, Economics of Innovation and New Technology, Taylor & Francis Journals (2019) View citations (2) (2019)

2017

6. The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)

2015

7. Listen to your Doctor, or else!: Medication Under-use and Overuse and Long-term Health Outcomes of Danish Diabetes Patients
   NBER Working Papers, National Bureau of Economic Research, Inc
8. Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010
   CESifo Working Paper Series, CESifo
   See also Journal Article Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010, International Journal of the Economics of Business, Taylor & Francis Journals (2015) (2015)
9. The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (7)
   See also Journal Article The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011, International Journal of Health Economics and Management, Springer (2015) View citations (7) (2015)

2013

10. The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
11. The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence
    CESifo Working Paper Series, CESifo
    See also Journal Article The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence, Social Science & Medicine, Elsevier (2015) (2015)

2012

12. Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)
13. The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (11)
    See also Journal Article The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files, Forum for Health Economics & Policy, De Gruyter (2013) View citations (10) (2013)
14. The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey
    NBER Working Papers, National Bureau of Economic Research, Inc
    See also Chapter The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans: Evidence from the 2004 National Nursing Home Survey, Advances in Health Economics and Health Services Research, Emerald Group Publishing Limited (2012) (2012)
15. The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data
    CESifo Working Paper Series, CESifo View citations (1)
    See also Journal Article The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data, Economics of Innovation and New Technology, Taylor & Francis Journals (2014) View citations (2) (2014)

2011

16. The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007
    NBER Working Papers, National Bureau of Economic Research, Inc
    See also Journal Article The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007, Social Science & Medicine, Elsevier (2013) View citations (4) (2013)

2010

17. Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (5)
    See also Journal Article Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia, Forum for Health Economics & Policy, De Gruyter (2010) View citations (5) (2010)
18. Has medical innovation reduced cancer mortality?
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
    See also Journal Article Has Medical Innovation Reduced Cancer Mortality?, CESifo Economic Studies, CESifo Group (2014) View citations (15) (2014)
19. Impact of Specialization on Health Outcomes – Evidence from U.S. Cancer Data
    SOI - Working Papers, Socioeconomic Institute - University of Zurich
20. The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France
    CESifo Working Paper Series, CESifo View citations (3)

2009

21. Response to Baker and Fugh-Berman's Critique of my Paper, "Why has Longevity Increased more in some States than in others?"
    CESifo Working Paper Series, CESifo View citations (1)
22. Spurious correlation in estimation of the health production function: A note
    SOI - Working Papers, Socioeconomic Institute - University of Zurich View citations (6)
    See also Journal Article Spurious correlation in estimation of the health production function: A note, Economics Bulletin, AccessEcon (2010) View citations (1) (2010)
23. The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (9)
    See also Journal Article The quality of medical care, behavioral risk factors, and longevity growth, International Journal of Health Economics and Management, Springer (2011) View citations (20) (2011)

2008

24. Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
    See also Journal Article Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003, Health Economics, John Wiley & Sons, Ltd. (2009) View citations (7) (2009)
25. Pharmaceutical innovation and the longevity of Australians: a first look
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (11)
    See also Chapter Pharmaceutical innovation and the longevity of Australians: A first look, Advances in Health Economics and Health Services Research, Emerald Group Publishing Limited (2008) (2008)

2006

26. Importation and Innovation
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
    See also Journal Article IMPORTATION AND INNOVATION, Economics of Innovation and New Technology, Taylor & Francis Journals (2007) View citations (7) (2007)
27. The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (7)
28. The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)

2004

29. The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
    See also Chapter The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program, Advances in Health Economics and Health Services Research, Emerald Group Publishing Limited (2010) (2010)
30. The Expanding Pharmaceutical Arsenal in the War on Cancer
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (12)
    Also in 2004 Meeting Papers, Society for Economic Dynamics (2004) View citations (12)

2003

31. Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (26)
32. The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (14)
    See also Journal Article The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001, International Journal of Health Economics and Management, Springer (2005) View citations (25) (2005)

2002

33. Benefits and Costs of Newer Drugs: An Update
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (13)
    See also Journal Article Benefits and costs of newer drugs: an update, Managerial and Decision Economics, John Wiley & Sons, Ltd. (2007) View citations (2) (2007)
34. Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health"
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (8)
    See also Journal Article Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health', Managerial and Decision Economics, John Wiley & Sons, Ltd. (2007) View citations (9) (2007)
35. Sources of U.S. Longevity Increase, 1960-1997
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (13)
    Also in CESifo Working Paper Series, CESifo (2000) View citations (1)
36. The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (31)
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (2002)
    See also Journal Article The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry, Journal of Law and Economics, University of Chicago Press (2002) View citations (30) (2002)
37. The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US
    Working Papers, Harris School of Public Policy Studies, University of Chicago
38. The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
39. The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (39)
40. Using Patents Data to Map Technical Change in Health-Related Areas
    OECD Science, Technology and Industry Working Papers, OECD Publishing View citations (2)

2001

41. Does foreign direct investment transfer technology across borders?
    ULB Institutional Repository, ULB -- Universite Libre de Bruxelles View citations (327)
    See also Journal Article Does Foreign Direct Investment Transfer Technology Across Borders?, The Review of Economics and Statistics, MIT Press (2001) View citations (337) (2001)
42. The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (5)
    Also in CESifo Working Paper Series, CESifo (2000) View citations (1)
43. The Effect of New Drugs on Mortality from Rare Diseases and HIV
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)

2000

44. The Impact of Hospital Quality-Related Practices on Health Outcomes
    Center for Policy Research Working Papers, Center for Policy Research, Maxwell School, Syracuse University

1998

45. International R&D spillovers comment
    ULB Institutional Repository, ULB -- Universite Libre de Bruxelles View citations (179)
    See also Journal Article International R&D spillovers: A comment, European Economic Review, Elsevier (1998) View citations (204) (1998)
46. Pharmaceutical Innovation, Mortality Reduction, and Economic Growth
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (24)
47. The Allocation of Publicly-Funded Biomedical Research
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)
    Also in CESifo Working Paper Series, CESifo (1997)
    See also Chapter The Allocation of Publicly Funded Biomedical Research, NBER Chapters, National Bureau of Economic Research, Inc (2001) View citations (13) (2001)

1997

48. The Impact and Organization of Publicly-Funded Research and Development in the European Community
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (19)
    See also Journal Article The Impact and Organization of Publicly-Funded Research and development in the European Community, Annals of Economics and Statistics, GENES (1998) View citations (15) (1998)

1996

49. Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
50. Computer Use and Productivity Growth in federal Government Agencies
    Working Papers, Columbia - Graduate School of Business View citations (4)
51. International R&D Spillovers: A Re-Examination
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (59)
52. The Effect of New Political Administration on Federal Government Productivity and Employment
    Working Papers, Columbia - Graduate School of Business View citations (1)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1996) View citations (1)
53. The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (12)
54. The European Strategic Program for Research in Information Technologie (ESPRIT): An Ex-Post Analysis
    Working Papers, Columbia - Graduate School of Business View citations (3)

1993

55. The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (55)

1992

56. Ownership Structure and Corporate Performance in Japan
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (43)
    See also Journal Article Ownership structure and corporate performance in Japan, Japan and the World Economy, Elsevier (1994) View citations (61) (1994)
57. R&D Investment and International Productivity Differences
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (125)

1991

58. Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability
    NBER Working Papers, National Bureau of Economic Research, Inc
    See also Journal Article Labour market institutions, liquidity constraints, and macroeconomic stability, Journal of Economic Behavior & Organization, Elsevier (1995) (1995)

1990

59. Industrial De-Diversification and Its Consequences for Productivity
    Economics Working Paper Archive, Levy Economics Institute View citations (5)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1990) View citations (33)
    See also Journal Article Industrial de-diversification and its consequences for productivity, Journal of Economic Behavior & Organization, Elsevier (1992) View citations (42) (1992)

1989

60. How Elastic is the Government's Demand for Weapons?
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)
    Also in Working Papers, Columbia - Graduate School of Business (1988)
    See also Journal Article How elastic is the government's demand for weapons?, Journal of Public Economics, Elsevier (1989) View citations (3) (1989)
61. THE EFFECT OF TAKEOVERS ON THE EMPLOYMENT AND WAGES OF CENTRAL-OFFICE AND OTHER PERSONNEL
    Working Papers, Columbia - Graduate School of Business View citations (4)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1989) View citations (12)
    Working Papers, U.S. Census Bureau, Center for Economic Studies (1989) View citations (4)
62. The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior
    Working Papers, U.S. Census Bureau, Center for Economic Studies View citations (9)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1989) View citations (85)
    See also Journal Article The effects of leveraged buyouts on productivity and related aspects of firm behavior, Journal of Financial Economics, Elsevier (1990) View citations (166) (1990)
63. The Effects of Mergers on Prices, Costs, And Capacity Utilization in the U.S. Air Transportation Industry, 1970-84
    Economics Working Paper Archive, Levy Economics Institute
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1989)
64. The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (72)
    See also Journal Article The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data, Economic Inquiry, Western Economic Association International (1991) View citations (157) (1991)
65. USING LINKED CENSUS R&D-LRD DATA TO ANALYZE THE EFFECT OF R&D INVESTMENT ON TOTAL FACTOR PRODUCTIVITY GROWTH
    Working Papers, U.S. Census Bureau, Center for Economic Studies View citations (5)

1988

66. CONTRIBUTIONS TO FEDERAL ELECTION CAMPAIGNS BY GOVERNMENT CONTRACTORS
    Working Papers, Columbia - Graduate School of Business
    See also Journal Article Contributions to Federal Election Campaigns by Government Contractors, Journal of Industrial Economics, Wiley Blackwell (1989) View citations (2) (1989)
67. CROWDING OUT: THE IMPACT OF THE STRATEGIC DEFENSE INITIATIVE ON U.S. CIVILIAN R&D INVESTMENT AND INDUSTRIAL COMPETITIVENESS
    Working Papers, Columbia - Graduate School of Business
68. GOVERNMENT SUBSIDIES TO PRIVATE MILITARY R&D INVESTMEN: DOD'S IR&D POLICY
    Working Papers, Columbia - Graduate School of Business View citations (4)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1988) View citations (3)
69. IR&D Project Data and Theories of R&D Investment
    NBER Working Papers, National Bureau of Economic Research, Inc
    See also Journal Article IR & D project data and theories of R & D investment, Journal of Economic Dynamics and Control, Elsevier (1989) View citations (1) (1989)
70. Technical Change, Learning, and Wages
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (7)

1986

71. Errors of Measurement in Output Deflators
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (14)
    See also Journal Article Errors of Measurement in Output Deflators, Journal of Business & Economic Statistics, American Statistical Association (1989) View citations (21) (1989)
72. Private Investment in R&D to Signal Ability to Perform Government Contracts
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)

1985

73. The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)

1982

74. R and D and Productivity at the Industry Level: Is There Still a Relationship?
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (12)

1981

75. Training, Tenure, and Productivity
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)

Journal Articles

2024

1. Has pharmaceutical innovation reduced the average cost of U.S. health care episodes?
   International Journal of Health Economics and Management, 2024, 24, (1), 1-31
2. The impact of biomedical innovation on the disability of elderly Medicare recipients, 2013–2019
   Economics of Innovation and New Technology, 2024, 33, (2), 344-361

2022

3. The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019
   Swiss Journal of Economics and Statistics, 2022, 158, (1), 1-24
4. The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries
   Economics & Human Biology, 2022, 46, (C) View citations (1)
5. The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017
   Journal of Evolutionary Economics, 2022, 32, (4), 1155-1173 View citations (1)

2021

6. Are drug prices subject to creative destruction? Evidence from the US, 1997–2017
   Health Economics, 2021, 30, (8), 1910-1932
7. The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998–2015
   Forum for Health Economics & Policy, 2021, 24, (1), 35-74

2020

8. Are patients more adherent to newer drugs?
   Health Care Management Science, 2020, 23, (4), 605-618 View citations (2)
9. The Health Impact of, and access to, New Drugs in Korea
   East Asian Economic Review, 2020, 24, (2), 127-164

2019

10. The long-run impact of new medical ideas on cancer survival and mortality
    Economics of Innovation and New Technology, 2019, 28, (7), 722-740 View citations (2)
    See also Working Paper The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality, NBER Working Papers (2018) View citations (2) (2018)

2018

11. THE IMPACT OF NEW DRUG LAUNCHES ON LIFE-YEARS LOST IN 2015 FROM 19 TYPES OF CANCER IN 36 COUNTRIES
    Journal of Demographic Economics, 2018, 84, (3), 309-354 View citations (1)
    Also in JODE - Journal of Demographic Economics, 2018, 84, (3), 309-354 (2018) View citations (4)
    See also Working Paper The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries, NBER Working Papers (2018) View citations (5) (2018)
12. The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis
    Forum for Health Economics & Policy, 2018, 21, (2), 20 View citations (2)
    See also Working Paper The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis, CESifo Working Paper Series (2019) (2019)
13. The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015
    Review of Middle East Economics and Finance, 2018, 14, (3), 15
14. The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013
    The American Economist, 2018, 63, (2), 147-165

2017

15. The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012
    Forum for Health Economics & Policy, 2017, 20, (1), 28 View citations (1)
16. The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia
    The Economic Record, 2017, 93, (302), 353-378 View citations (3)
17. The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013
    Latin American Economic Review, 2017, 26, (1), 1-22 View citations (1)

2015

18. Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010
    International Journal of the Economics of Business, 2015, 22, (2), 277-299
    See also Working Paper Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010, CESifo Working Paper Series (2015) (2015)
19. The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010
    Applied Health Economics and Health Policy, 2015, 13, (2), 207-222 View citations (2)
20. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011
    International Journal of Health Economics and Management, 2015, 15, (3), 339-359 View citations (7)
    See also Working Paper The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011, NBER Working Papers (2015) View citations (7) (2015)
21. The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence
    Social Science & Medicine, 2015, 130, (C), 162-171
    See also Working Paper The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence, CESifo Working Paper Series (2013) (2013)

2014

22. Has Medical Innovation Reduced Cancer Mortality?
    CESifo Economic Studies, 2014, 60, (1), 135-177 View citations (15)
    See also Working Paper Has medical innovation reduced cancer mortality?, NBER Working Papers (2010) View citations (6) (2010)
23. The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010
    Journal of Human Capital, 2014, 8, (4), 432 - 480 View citations (9)
24. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010
    Health Policy, 2014, 117, (3), 361-373 View citations (3)
25. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009
    Economics & Human Biology, 2014, 13, (C), 107-127 View citations (7)
26. The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data
    Economics of Innovation and New Technology, 2014, 23, (3), 239-273 View citations (2)
    See also Working Paper The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data, CESifo Working Paper Series (2012) View citations (1) (2012)

2013

27. The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files
    Forum for Health Economics & Policy, 2013, 16, (1), 1-33 View citations (10)
    See also Working Paper The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files, NBER Working Papers (2012) View citations (11) (2012)
28. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007
    The European Journal of Health Economics, 2013, 14, (1), 41-56 View citations (3)
29. The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007
    Social Science & Medicine, 2013, 77, (C), 50-59 View citations (4)
    See also Working Paper The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007, NBER Working Papers (2011) (2011)

2012

30. Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7
    PharmacoEconomics, 2012, 30, (3), 197-211 View citations (12)
31. Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization
    International Review of Law and Economics, 2012, 32, (1), 95-109 View citations (11)

2011

32. Has Pharmaceutical Innovation Reduced Social Security Disability Growth?
    International Journal of the Economics of Business, 2011, 18, (2), 293-316
33. The quality of medical care, behavioral risk factors, and longevity growth
    International Journal of Health Economics and Management, 2011, 11, (1), 1-34 View citations (20)
    See also Working Paper The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth, NBER Working Papers (2009) View citations (9) (2009)

2010

34. Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia
    Forum for Health Economics & Policy, 2010, 13, (2), 18 View citations (5)
    See also Working Paper Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia, NBER Working Papers (2010) View citations (5) (2010)
35. Pharmaceutical Price Discrimination and Social Welfare
    Capitalism and Society, 2010, 5, (1), 32 View citations (6)
36. Pharmaceutical innovation and mortality in the United States, 1960-2000. A commentary on Schnittker and Karandinos
    Social Science & Medicine, 2010, 70, (7), 969-971
37. Spurious correlation in estimation of the health production function: A note
    Economics Bulletin, 2010, 30, (3), 2505-2514 View citations (1)
    See also Working Paper Spurious correlation in estimation of the health production function: A note, SOI - Working Papers (2009) View citations (6) (2009)

2009

38. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003
    Health Economics, 2009, 18, (5), 519-534 View citations (7)
    See also Working Paper Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003, NBER Working Papers (2008) View citations (2) (2008)
39. The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004
    Economics of Innovation and New Technology, 2009, 18, (5), 407-428 View citations (16)

2008

40. Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data
    Forum for Health Economics & Policy, 2008, 10, (1), 27 View citations (2)
    See also Chapter Pharmaceutical Innovation and US Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data, NBER Chapters, 2007 (2007) (2007)

2007

41. Benefits and costs of newer drugs: an update
    Managerial and Decision Economics, 2007, 28, (4-5), 485-490 View citations (2)
    See also Working Paper Benefits and Costs of Newer Drugs: An Update, NBER Working Papers (2002) View citations (13) (2002)
42. IMPORTATION AND INNOVATION
    Economics of Innovation and New Technology, 2007, 16, (6), 403-417 View citations (7)
    See also Working Paper Importation and Innovation, NBER Working Papers (2006) View citations (3) (2006)
43. Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health'
    Managerial and Decision Economics, 2007, 28, (4-5), 371-392 View citations (9)
    See also Working Paper Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health", NBER Working Papers (2002) View citations (8) (2002)
44. The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data
    American Economic Review, 2007, 97, (2), 438-443 View citations (17)

2006

45. Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes?
    Swiss Journal of Economics and Statistics (SJES), 2006, 142, (V), 69-75
46. The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003
    PharmacoEconomics, 2006, 24, (3), 5-25 View citations (9)

2005

47. Are the More Educated More Likely to Use New Drugs?
    Annals of Economics and Statistics, 2005, (79-80), 671-696 View citations (39)
    See also Chapter Are the More Educated More Likely to Use New Drugs?, NBER Chapters, 2010, 671-696 (2010) View citations (3) (2010)
48. The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001
    International Journal of Health Economics and Management, 2005, 5, (1), 47-73 View citations (25)
    See also Working Paper The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001, NBER Working Papers (2003) View citations (14) (2003)

2004

49. Sources of U.S. longevity increase, 1960-2001
    The Quarterly Review of Economics and Finance, 2004, 44, (3), 369-389 View citations (27)

2003

50. The benefits to society of new drugs: a survey of the econometric evidence
    Proceedings, 2003, (Sep), 43-59 View citations (2)
51. The effect of new drug approvals on HIV mortality in the US, 1987-1998
    Economics & Human Biology, 2003, 1, (2), 259-266 View citations (3)

2002

52. The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry
    Journal of Law and Economics, 2002, 45, (S2), 643-672 View citations (30)
    See also Working Paper The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry, NBER Working Papers (2002) View citations (31) (2002)
53. The Effects of Medicare on Health Care Utilization and Outcomes
    Forum for Health Economics & Policy, 2002, 5, (1), 29 View citations (36)
    See also Chapter The Effects of Medicare on Health Care Utilization and Outcomes, NBER Chapters, 2002, 27-52 (2002) View citations (32) (2002)

2001

54. Does Foreign Direct Investment Transfer Technology Across Borders?
    The Review of Economics and Statistics, 2001, 83, (3), 490-497 View citations (337)
    See also Working Paper Does foreign direct investment transfer technology across borders?, ULB Institutional Repository (2001) View citations (327) (2001)

1999

55. Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993
    Canadian Journal of Economics, 1999, 32, (2), 335-362 View citations (58)
56. Managerial ownership and firm performance: A re-examination using productivity measurement
    Journal of Corporate Finance, 1999, 5, (4), 323-339 View citations (71)

1998

57. Computer Use and Productivity Growth in US Federal Government Agencies, 1987–92
    Journal of Industrial Economics, 1998, 46, (2), 257-279 View citations (15)
58. International R&D spillovers: A comment
    European Economic Review, 1998, 42, (8), 1483-1491 View citations (204)
    See also Working Paper International R&D spillovers comment, ULB Institutional Repository (1998) View citations (179) (1998)
59. The Impact and Organization of Publicly-Funded Research and development in the European Community
    Annals of Economics and Statistics, 1998, (49-50), 199-222 View citations (15)
    See also Working Paper The Impact and Organization of Publicly-Funded Research and Development in the European Community, NBER Working Papers (1997) View citations (19) (1997)

1996

60. Book Reviews
    Journal of Economics, 1996, 63, (3), 325-345
61. Do (More and Better) Drugs Keep People Out of Hospitals?
    American Economic Review, 1996, 86, (2), 384-88 View citations (41)

1995

62. Labour market institutions, liquidity constraints, and macroeconomic stability
    Journal of Economic Behavior & Organization, 1995, 28, (1), 145-154
    See also Working Paper Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability, NBER Working Papers (1991) (1991)
63. Rejoinder to comment by Maarten Vendrik
    Journal of Economic Behavior & Organization, 1995, 28, (3), 455-456

1994

64. Ownership structure and corporate performance in Japan
    Japan and the World Economy, 1994, 6, (3), 239-261 View citations (61)
    See also Working Paper Ownership Structure and Corporate Performance in Japan, NBER Working Papers (1992) View citations (43) (1992)
65. Testing the Convergence Hypothesis
    The Review of Economics and Statistics, 1994, 76, (3), 576-79 View citations (89)

1992

66. Industrial de-diversification and its consequences for productivity
    Journal of Economic Behavior & Organization, 1992, 18, (3), 427-438 View citations (42)
    See also Working Paper Industrial De-Diversification and Its Consequences for Productivity, Economics Working Paper Archive (1990) View citations (5) (1990)

1991

67. The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data
    Economic Inquiry, 1991, 29, (2), 203-29 View citations (157)
    See also Working Paper The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data, NBER Working Papers (1989) View citations (72) (1989)
68. The Managerial Response to Regulation of Financial Reporting for Segments of a Business Enterprise
    Journal of Regulatory Economics, 1991, 3, (3), 241-49 View citations (14)

1990

69. Issues in measuring industrial R&D
    Research Policy, 1990, 19, (2), 157-163 View citations (4)
70. The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel
    Journal of Law and Economics, 1990, 33, (2), 383-408 View citations (49)
71. The effects of leveraged buyouts on productivity and related aspects of firm behavior
    Journal of Financial Economics, 1990, 27, (1), 165-194 View citations (166)
    See also Working Paper The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior, Working Papers (1989) View citations (9) (1989)

1989

72. Contributions to Federal Election Campaigns by Government Contractors
    Journal of Industrial Economics, 1989, 38, (1), 31-48 View citations (2)
    See also Working Paper CONTRIBUTIONS TO FEDERAL ELECTION CAMPAIGNS BY GOVERNMENT CONTRACTORS, Working Papers (1988) (1988)
73. Errors of Measurement in Output Deflators
    Journal of Business & Economic Statistics, 1989, 7, (1), 1-9 View citations (21)
    See also Working Paper Errors of Measurement in Output Deflators, NBER Working Papers (1986) View citations (14) (1986)
74. How elastic is the government's demand for weapons?
    Journal of Public Economics, 1989, 40, (1), 57-78 View citations (3)
    See also Working Paper How Elastic is the Government's Demand for Weapons?, NBER Working Papers (1989) View citations (4) (1989)
75. IR & D project data and theories of R & D investment
    Journal of Economic Dynamics and Control, 1989, 13, (2), 271-282 View citations (1)
    See also Working Paper IR&D Project Data and Theories of R&D Investment, NBER Working Papers (1988) (1988)
76. THE EFFECT OF CONTROL CHANGES ON THE PRODUCTIVITY OF U.S. MANUFACTURING PLANTS
    Journal of Applied Corporate Finance, 1989, 2, (2), 60-67 View citations (5)

1988

77. Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data
    The Review of Economics and Statistics, 1988, 70, (3), 421-30 View citations (22)
78. The Private R&D Investment Response to Federal Design and Technical Competitions
    American Economic Review, 1988, 78, (3), 550-59 View citations (119)
79. The burden of government:, Stanford: Hoover Institution Press, 1986. x + 188 pp., $23.95
    Journal of Comparative Economics, 1988, 12, (2), 304-305

1987

80. Changing market opportunities and the structure of R & D investment: The case of energy
    Energy Economics, 1987, 9, (3), 154-158 View citations (1)
81. Productivity and Changes in Ownership of Manufactoring Plants
    Brookings Papers on Economic Activity, 1987, 18, (3, Special Issue on Microeconomics), 643-684 View citations (98)
82. The Comparative Advantage of Educated Workers in Implementing New Technology
    The Review of Economics and Statistics, 1987, 69, (1), 1-11 View citations (494)
83. The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment
    Journal of Industrial Economics, 1987, 36, (1), 97-104 View citations (68)

1986

84. Energy prices and induced innovation
    Research Policy, 1986, 15, (2), 67-75 View citations (22)

1984

85. Interindustry Technology Flows and Productivity Growth: A Re-examination
    The Review of Economics and Statistics, 1984, 66, (2), 324-29 View citations (127)
86. The Relationship between Federal Contract R&D and Company R&D
    American Economic Review, 1984, 74, (2), 73-78 View citations (83)

Chapters

2022

1. The impact of biomedical innovation on longevity and health
   Chapter 23 in Elgar Encyclopedia on the Economics of Knowledge and Innovation, 2022, pp 186-198

2018

2. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger
   A chapter in Economic Dimensions of Personalized and Precision Medicine, 2018, pp 273-304

2016

3. The Impact of Biomedical Research on U.S. Cancer Mortality: A Bibliometric Analysis
   A chapter in Measuring and Modeling Health Care Costs, 2016, pp 475-504

2012

4. The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans: Evidence from the 2004 National Nursing Home Survey
   A chapter in The Economics of Medical Technology, 2012, pp 73-101
   See also Working Paper The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey, National Bureau of Economic Research, Inc (2012) (2012)

2010

5. Are the More Educated More Likely to Use New Drugs?
   A chapter in Contributions in Memory of Zvi Griliches, 2010, pp 671-696 View citations (3)
   See also Journal Article Are the More Educated More Likely to Use New Drugs?, GENES (2005) View citations (39) (2005)
6. The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program
   A chapter in Pharmaceutical Markets and Insurance Worldwide, 2010, pp 273-292
   See also Working Paper The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program, National Bureau of Economic Research, Inc (2004) View citations (1) (2004)

2008

7. Pharmaceutical innovation and the longevity of Australians: A first look
   A chapter in Beyond Health Insurance: Public Policy to Improve Health, 2008, pp 95-117
   See also Working Paper Pharmaceutical innovation and the longevity of Australians: a first look, National Bureau of Economic Research, Inc (2008) View citations (11) (2008)

2007

8. Pharmaceutical Innovation and US Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data
   A chapter in Frontiers in Health Policy Research, Volume 10, 2007
   See also Journal Article Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data, De Gruyter (2008) View citations (2) (2008)

2005

9. Pharmaceutical Knowledge-Capital Accumulation and Longevity
   A chapter in Measuring Capital in the New Economy, 2005, pp 237-274 View citations (8)

2002

10. The Effects of Medicare on Health Care Utilization and Outcomes
    A chapter in Frontiers in Health Policy Research, Volume 5, 2002, pp 27-52 View citations (32)
    See also Journal Article The Effects of Medicare on Health Care Utilization and Outcomes, De Gruyter (2002) View citations (36) (2002)

2001

11. The Allocation of Publicly Funded Biomedical Research
    A chapter in Medical Care Output and Productivity, 2001 View citations (13)
    See also Working Paper The Allocation of Publicly-Funded Biomedical Research, National Bureau of Economic Research, Inc (1998) View citations (4) (1998)

1995

12. Economics of defense R&D
    Chapter 15 in Handbook of Defense Economics, 1995, vol. 1, pp 431-457 View citations (20)

1984

13. R&D and Productivity Growth at the Industry Level: Is There Still a Relationship?
    A chapter in R&D, Patents, and Productivity, 1984, pp 465-502 View citations (131)